What is a stock summary page? Click here for an overview.
Business Description
G1 Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US3621LQ1099
Compare
Compare
Traded in other countries / regions
GTHX.USAG1H.Germany Index Membership
Russell 2000 IPO Date
2017-05-17Description
G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat the types of cancer, such as cell lung cancer and breast cancer, and designs them to combine and enhance the anti-tumor activity of current therapies. Its product COSELA indicates to help protect bone marrow from the damage of chemotherapy.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.27 | |||||
| Equity-to-Asset | 0.25 | |||||
| Debt-to-Equity | 1.95 | |||||
| Debt-to-EBITDA | -1.43 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -8.11 | |||||
| Beneish M-Score | -2.81 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.1 | |||||
| 3-Year EBITDA Growth Rate | 35.9 | |||||
| 3-Year EPS without NRI Growth Rate | 29.2 | |||||
| 3-Year FCF Growth Rate | 30.5 | |||||
| 3-Year Book Growth Rate | -47.3 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 11.28 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 79.46 | |||||
| 9-Day RSI | 84.36 | |||||
| 14-Day RSI | 84.37 | |||||
| 3-1 Month Momentum % | 177.73 | |||||
| 6-1 Month Momentum % | 121.5 | |||||
| 12-1 Month Momentum % | 377.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.48 | |||||
| Quick Ratio | 2.12 | |||||
| Cash Ratio | 1.62 | |||||
| Days Inventory | 801.57 | |||||
| Days Sales Outstanding | 73.74 | |||||
| Days Payable | 325.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.9 | |||||
| Shareholder Yield % | 6.5 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 89.44 | |||||
| Operating Margin % | -65.09 | |||||
| Net Margin % | -76.93 | |||||
| FCF Margin % | -64.51 | |||||
| ROE % | -118.89 | |||||
| ROA % | -37.11 | |||||
| ROIC % | -225.16 | |||||
| 3-Year ROIIC % | -7678.33 | |||||
| ROC (Joel Greenblatt) % | -369.24 | |||||
| ROCE % | -39.03 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 134.91 | |||||
| PS Ratio | 6.4 | |||||
| PB Ratio | 15.31 | |||||
| Price-to-Tangible-Book | 15.21 | |||||
| EV-to-EBIT | -10.71 | |||||
| EV-to-EBITDA | -10.87 | |||||
| EV-to-Revenue | 6.26 | |||||
| EV-to-Forward-Revenue | 3.85 | |||||
| EV-to-FCF | -9.71 | |||||
| Price-to-GF-Value | 1.13 | |||||
| Price-to-Net-Current-Asset-Value | 19.86 | |||||
| Earnings Yield (Greenblatt) % | -9.34 | |||||
| FCF Yield % | -9.95 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GTHX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
G1 Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 58.195 | ||
| EPS (TTM) ($) | -0.86 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | 0.31 | ||
| 3-Year Sortino Ratio | 0.6 | ||
| Volatility % | 131.67 | ||
| 14-Day RSI | 84.37 | ||
| 14-Day ATR ($) | 0.076125 | ||
| 20-Day SMA ($) | 7.1265 | ||
| 12-1 Month Momentum % | 377.18 | ||
| 52-Week Range ($) | 1.08 - 7.19 | ||
| Shares Outstanding (Mil) | 52.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
G1 Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
G1 Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
G1 Therapeutics Inc Frequently Asked Questions
What is G1 Therapeutics Inc(GTHX)'s stock price today?
The current price of GTHX is $7.15. The 52 week high of GTHX is $7.19 and 52 week low is $1.08.
When is next earnings date of G1 Therapeutics Inc(GTHX)?
The next earnings date of G1 Therapeutics Inc(GTHX) is 2025-05-01 Est..
Does G1 Therapeutics Inc(GTHX) pay dividends? If so, how much?
G1 Therapeutics Inc(GTHX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers